Bifalgorithm post · Canada has the strengths to lead in life sciences · Strength meets a structural gap
Access Gap
Access Gap (Canada has the strengths to lead in life sciences · Strength meets a structural gap) — "That is where the gap persists. Despite receiving Health Ca…
Ideas in this flowchart
- The gap between Health Canada approval and patient access persists.
- A growing number of approved medicines are not reaching patients.
- Only 21 per cent of new medicines become available through Canadian public plans.
- For medicines that become available, Canadians wait an average of two years after approval.
- This is the longest wait among the G7 countries.
- The delays are especially consequential for people living with serious or complex conditions.
- Delays can negatively affect health outcomes.
- Delays can reduce quality of life.
